You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractor Palmetto for the week of 8/22/2019.
Canaccord Genuity began coverage of Castle Biosciences with a Buy rating and a $26 price target, while SVB Leerink assigned an Outperform rating and a $28 price target.
The company markets two tests for skin cancer, including DecisionDx-Melanoma for identifying high-risk Stage I and II cutaneous melanoma patients.
The company markets genetic tests for skin cancer including DecisionDx-Melanoma for identifying high-risk stage I and II cutaneous melanoma patients.
BrightEdge was founded by the American Cancer Society to invest in for-profit companies developing novel cancer therapeutics and diagnostics.
Palmetto GBA issued final local coverage determination for the tissue-based, 31-gene expression test, which determines a patient’s risk for metastatic disease.
The approvals allow the company to offer its PCR-based expression profile cancer risk tests in the state.
The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.
Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.
Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.
An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.
Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.
In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.